| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the NMR Research Group, Institute of Neurology, Queen Square, London, England.
In the planning of MRI protocols to monitor disease activity in multiple sclerosis (MS), the clinical subtype needs to be considered. In this serial gadolinium-enhanced MRI study, we demonstrated differences between patients with early relapsing/remitting MS and benign MS in both the production of new lesions and the occurrence of enhancement.
Address correspondence and reprint requests to Dr. Alan J. Thompson, Institute of Neurology, Queen Square, London WC1N 3BG, England.
The NMR Research Group is supported by The Multiple Sclerosis Society of Great Britain and Northern Ireland and the Medical Research Council of Great Britain.
Received April 1, 1991. Accepted for publication in final form June 14, 1991.
This article has been cited by other articles:
|
|
 |
|
  M. Rovaris, F. Barkhof, M. Calabrese, N. De Stefano, F. Fazekas, D. H. Miller, X. Montalban, C. Polman, M. A. Rocca, A. J. Thompson, et al. MRI features of benign multiple sclerosis: Toward a new definition of this disease phenotype Neurology, May 12, 2009; 72(19): 1693 - 1701. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Soelberg Sorensen Review: Neutralizing antibodies against interferon-beta Therapeutic Advances in Neurological Disorders, September 1, 2008; 1(2): 125 - 141. [Abstract] [PDF]
|
|
|
|
|
|
O. Khan Can clinical outcomes be used to detect neuroprotection in multiple sclerosis? Neurology, May 29, 2007; 68(22_suppl_3): S64 - S71. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Zivadinov Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis? Neurology, May 29, 2007; 68(22_suppl_3): S72 - S82. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W Rashid, G R Davies, D T Chard, C M Griffin, D R Altmann, A J Thompson, and D H Miller Relationship of triple dose contrast enhanced lesions with clinical measures and brain atrophy in early relapsing-remitting multiple sclerosis: a two-year longitudinal study Multiple Sclerosis, March 1, 2007; 13(2): 178 - 185. [Abstract] [PDF]
|
|
|
|
|
|
D R Smith, B Weinstock-Guttman, J A Cohen, X Wei, C Gutmann, R Bakshi, M Olek, L Stone, S Greenberg, D Stuart, et al. A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta Multiple Sclerosis, October 1, 2005; 11(5): 573 - 582. [Abstract] [PDF]
|
|
|
|
|
|
A. Minneboo, B. M. J. Uitdehaag, H. J. Ader, F. Barkhof, C. H. Polman, and J. A. Castelijns Patterns of enhancing lesion evolution in multiple sclerosis are uniform within patients Neurology, July 12, 2005; 65(1): 56 - 61. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T L Vollmer, J T Phillips, A D Goodman, M A Agius, M A Libonati, J L Giacchino, and J S Grundy An open-label safety and drug interaction study of natalizumab (AntegrenTM) in combination with interferon-beta (Avonex(R)) in patients with multiple sclerosis Multiple Sclerosis, October 1, 2004; 10(5): 511 - 520. [Abstract] [PDF]
|
|
|
|
 |
|
 W Rashid, L M Parkes, G T Ingle, D T Chard, A T Toosy, D R Altmann, M R Symms, P S Tofts, A J Thompson, and D H Miller Abnormalities of cerebral perfusion in multiple sclerosis J. Neurol. Neurosurg. Psychiatry, September 1, 2004; 75(9): 1288 - 1293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Cotton, H. L. Weiner, F. A. Jolesz, and C. R.G. Guttmann MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals Neurology, February 25, 2003; 60(4): 640 - 646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Miller, O. A. Khan, W. A. Sheremata, L. D. Blumhardt, G. P.A. Rice, M. A. Libonati, A. J. Willmer-Hulme, C. M. Dalton, K. A. Miszkiel, P. W. O'Connor, et al. A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis N. Engl. J. Med., January 2, 2003; 348(1): 15 - 23. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Brod Ingested Type I Interferon: State of the Art as Treatment for Autoimmunity Experimental Biology and Medicine, December 1, 2002; 227(11): 981 - 988. [Abstract] [Full Text]
|
|
|
|
|
|
E. M. Frohman, H. Zhang, P. D. Kramer, J. Fleckenstein, K. Hawker, M. K. Racke, and T. C. Frohman MRI characteristics of the MLF in MS patients with chronic internuclear ophthalmoparesis Neurology, September 11, 2001; 57(5): 762 - 768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Brod, J. W. Lindsey, F. S. Vriesendorp, C. Ahn, E. Henninger, P. A. Narayana, and J. S. Wolinsky Ingested IFN-{alpha}: Results of a pilot study in relapsing-remitting MS Neurology, September 11, 2001; 57(5): 845 - 852. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ge, R. I. Grossman, J. K. Udupa, J. S. Babb, L. G. Nyul, and D. L. Kolson Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: Fractional Volumetric Analysis of Gray Matter and White Matter Radiology, September 1, 2001; 220(3): 606 - 610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N C Silver, P S Tofts, M R Symms, G J Barker, A J Thompson, and D H Miller Quantitative contrast-enhanced magnetic resonance imaging to evaluate blood-brain barrier integrity in multiple sclerosis: a preliminary study Multiple Sclerosis, April 1, 2001; 7(2): 75 - 82. [Abstract] [PDF]
|
|
|
|
|
|
N A Losseff, D H Miller, D Kidd, and A J Thompson The predictive value of gadolinium enhancement for long term disability in relapsing-remitting multiple sclerosis-preliminary results Multiple Sclerosis, February 1, 2001; 7(1): 23 - 25. [Abstract] [PDF]
|
|
|
|
 |
|
 D. J. Werring, D. Brassat, A. G. Droogan, C. A. Clark, M. R. Symms, G. J Barker, D. G. MacManus, A. J. Thompson, and D. H. Miller The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: A serial diffusion MRI study Brain, August 1, 2000; 123(8): 1667 - 1676. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Roychowdhury, J. A. Maldjian, and R. I. Grossman Multiple Sclerosis: Comparison of Trace Apparent Diffusion Coefficients with MR Enhancement Pattern of Lesions AJNR Am. J. Neuroradiol., May 1, 2000; 21(5): 869 - 874. [Abstract] [Full Text]
|
|
|
|
|
|
O. Gonen, I. Catalaa, J. S. Babb, Y. Ge, L. J. Mannon, D. L. Kolson, and R. I. Grossman Total brain N-acetylaspartate: A new measure of disease load in MS Neurology, January 11, 2000; 54(1): 15 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Gasperini, C. Pozzilli, S. Bastianello, E. Giugni, M. A Horsfield, T. Koudriavtseva, S. Galgani, A. Paolillo, S. Haggiag, E. Millefiorini, et al. Interferon-beta -1a in relapsing-remitting multiple sclerosis: effect on hypointense lesion volume on T1 weighted images J. Neurol. Neurosurg. Psychiatry, November 1, 1999; 67(5): 579 - 584. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Miki, R. I. Grossman, J. K. Udupa, L. Wei, M. Polansky, L. J. Mannon, and D. L. Kolson Relapsing-Remitting Multiple Sclerosis: Longitudinal Analysis of MR Images-Lack of Correlation between Changes in T2 Lesion Volume and Clinical Findings Radiology, November 1, 1999; 213(2): 395 - 399. [Abstract] [Full Text]
|
|
|
|
|
|
F. Fazekas, F. Barkhof, M. Filippi, R. I. Grossman, D. K. B. Li, W. I. McDonald, H. F. McFarland, D. W. Paty, J. H. Simon, J. S. Wolinsky, et al. The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis Neurology, August 1, 1999; 53(3): 448 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Lee, S. Smith, J. Palace, S. Narayanan, N. Silver, L. Minicucci, M. Filippi, D. H. Miller, D. L. Arnold, and P. M. Matthews Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis? Brain, July 1, 1999; 122(7): 1261 - 1270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Sheremata, T. L. Vollmer, L. A. Stone, A. J. Willmer-Hulme, and M. Koller A safety and pharmacokinetic study of intravenous natalizumab in patients with MS Neurology, March 1, 1999; 52(5): 1072 - 1072. [Abstract] [Full Text]
|
|
|
|
|
|
M. Filippi, G. Iannucci, C. Tortorella, L. Minicucci, M. A. Horsfield, B. Colombo, M. P. Sormani, and G. Comi Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI Neurology, February 1, 1999; 52(3): 588 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J I O'Riordan, M G. Cain, A Coles, L Wang, D A. Compston, P Tofts, and D H Miller T1 hypointense lesion load in secondary progressive multiple sclerosis: a comparison of pre versus post contrast loads and of manual versus semi automated threshold techniques for lesion segmentation Multiple Sclerosis, October 1, 1998; 4(5): 408 - 412. [Abstract] [PDF]
|
|
|
|
|
|
S Edwards, M Zvartau, H Clarke, W Irving, and L D Blumhardt Clinical relapses and disease activity on magnetic resonance imaging associated with viral upper respiratory tract infections in multiple sclerosis J. Neurol. Neurosurg. Psychiatry, June 1, 1998; 64(6): 736 - 741. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G Giovannoni, A J. Green, and E J Thompson Are there any body fluid markers of brain atrophy in multiple sclerosis? Multiple Sclerosis, June 1, 1998; 4(3): 138 - 142. [Abstract] [PDF]
|
|
|
|
 |
|
 B. W. van Oosten, F. Barkhof, P. E. T. Scholten, B. M. E. von Blomberg, H. J. Ader, and C. H. Polman Increased Production of Tumor Necrosis Factor {alpha}, and Not of Interferon {gamma}, Preceding Disease Activity in Patients With Multiple Sclerosis Arch Neurol, June 1, 1998; 55(6): 793 - 798. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Khoury and H. L. Weiner Multiple Sclerosis: What Have We Learned From Magnetic Resonance Imaging Studies? Arch Intern Med, March 23, 1998; 158(6): 565 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N Tubridy, H J Ader, F Barkhof, A J Thompson, and D H Miller Exploratory treatment trials in multiple sclerosis using MRI: sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups J. Neurol. Neurosurg. Psychiatry, January 1, 1998; 64(1): 50 - 55. [Abstract] [Full Text]
|
|
|
|
|
|
C A Davie, G J Barker, A J Thompson, P S Tofts, W I McDonald, and D H Miller 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis J. Neurol. Neurosurg. Psychiatry, December 1, 1997; 63(6): 736 - 742. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L Truyen, F Barkhof, M Tas, M. Van Walderveen, S. Frequin, O. Hommes, J. Nauta, C. Polman, and J Valk Specific power calculations for magnetic resonance imaging (MRI) in monitoring active relapsing-remitting multiple sclerosis (MS): implications for phase II therapeutic trials Multiple Sclerosis, January 1, 1997; 2(6): 283 - 290. [Abstract] [PDF]
|
|
|
|
|
|
D. Gilden, M. Devlin, M. Burgoon, and G. Owens The search for virus in multiple sclerosis brain Multiple Sclerosis, November 1, 1996; 2(4): 179 - 183. [Abstract] [PDF]
|
|
|
|
|
|
G. Owens, M. Burgoon, M. Devlin, and D. Gilden Strategies to identify sequences or antigens unique to multiple sclerosis Multiple Sclerosis, November 1, 1996; 2(4): 184 - 194. [Abstract] [PDF]
|
|
|
|
|
|
D. Miller Guidelines for MRI monitoring of the treatment of multiple sclerosis: recommendations of the US Multiple Sclerosis Society's task force Multiple Sclerosis, June 1, 1996; 1(6): 335 - 338. [Abstract] [PDF]
|
|
|
|
|
|
B. vanOosten, M Lai, F Barkhof, D. Miller, I. Moseley, A. Thompson, S Hodgkinson, and C. Polman A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis Multiple Sclerosis, June 1, 1996; 1(6): 339 - 342. [Abstract] [PDF]
|
|
|
|
|
|
D. E. Goodkin, R. A. Rudick, and J. S. Ross The Use of Brain Magnetic Resonance Imaging in Multiple Sclerosis Arch Neurol, May 1, 1994; 51(5): 505 - 516. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
